Clinical Trials Directory

Trials / Completed

CompletedNCT01731756

Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis

Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis: Randomized, Double Blind, Placebo-controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Effects of leaf extract of Azadirachta indica in palmer arsenical keratosis: Randomized, double-blind, placebo-control trial

Detailed description

The objective of this study is to evaluate the effectiveness of topical administration of the Leaf of Azadirachta indica in the treatment of palmer arsenical keratosis. Fifty patients of moderate palmer arsenical keratosis patients from an arsenic affected area will be recruited on the basis of inclusion and exclusion criteria and had been drinking arsenic contaminated water for more than six months. They will be divided into two groups each will consist of twenty five members. One group will be provided A. indica plus 6% salicylic acid ointment to apply on palm overnight daily for 12 weeks. Another group will be provided 6% salicylic acid ointment . Water and nail sample will be collected before starting recruitment to confirm diagnosis. Then again nail sample will be collected before and after the study to see the level of arsenic in skin. Effects will be observed after every two weeks and change will be detected as nil, mild reduction, moderate reduction and fully cured.

Conditions

Interventions

TypeNameDescription
OTHERLeaf extract of A. indicaLeaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
DRUGSalicylic Acid (6%)Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
OTHERPetroleum jellyPetroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.

Timeline

Start date
2013-01-01
Primary completion
2013-12-01
Completion
2014-03-01
First posted
2012-11-22
Last updated
2014-05-05

Locations

1 site across 1 country: Bangladesh

Source: ClinicalTrials.gov record NCT01731756. Inclusion in this directory is not an endorsement.